Peter Vink, Josep Maria Ramon Torrell, Ana Sanchez Fructuoso, Sung-Joo Kim, Sang-Il Kim, Jeff Zaltzman, Fernanda Ortiz, Josep Maria Campistol Plana, Ana Maria Fernandez Rodriguez, Henar Rebollo Rodrigo, Magda Campins Marti, Rafael Perez, Francisco Manuel González Roncero, Deepali Kumar, Yang-Jen Chiang, Karen Doucette, Lissa Pipeleers, Maria Luisa Agüera Morales, Maria Luisa Rodriguez-Ferrero, Antonio Secchi, Shelly A McNeil, Laura Campora, Emmanuel Di Paolo, Mohamed El Idrissi, Marta López-Fauqued, Bruno Salaun, Thomas C Heineman, Lidia Oostvogels
BACKGROUND: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. METHODS: In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1-2 months (M) apart 4-18M posttransplant...
January 2, 2020: Clinical Infectious Diseases